Management of pediatric patients with cancer is complex and requires multidisciplinary coordination to organize cancer treatment and supportive care during treatment. In addition, care coordination is essential during the survivorship and end-of-life phases of pediatric cancer treatment.

Case managers and medical directors are challenged to maintain a high awareness of the recent therapeutic advances in the management of FL and DLBCL in order to develop an efficient coordinated treatment approach that incorporates novel therapies in the appropriate patient population.

Minimally invasive surgical techniques for endometrial cancers, particularly robotic-assisted laparoscopy, have been shown to decrease surgical morbidity and improve 30-day postoperative outcomes for appropriately selected patients with endometrial cancer. Despite evidence of improved outcomes, disparities persist in awareness of and access to minimally invasive surgery.

For patients with advanced RCC, several factors are taken into consideration to help determine which systemic regimen to consider in the first-line and subsequent line therapy. It is important for clinicians to understand when to use regimens for their patient’s unique clinical situation and how to treatment for patients with metastatic RCC requiring second, third, fourth, or further lines of therapy.

It is important for clinicians to be aware of the updated criteria to appropriately select patients who are sensitive to HER2-targeted agents; to stay up-to-date with evolving treatment strategies; to understand how to choose optimal treatment based on patient preference, toxicities, and drug availability; and to effectively evaluate patients during therapies and manage any therapy-related adverse effects.

Informing clinicians about emerging strategies for pediatric ALL management will shed light on new prognostic markers that could be targeted in pediatric ALL to enhance therapeutic efficacy and minimize short- and long-term treatment-related toxicities.

Triple-negative breast cancer is an aggressive subtype that is associated with poor outcomes. Staying up-to-date on current and emerging treatment options is important to integrate new evidence-based data into their clinical practice and optimize patient outcomes.

The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.

During this tumor board, faculty will discuss the emerging role of tumor and germline genetic testing and the treatment of advanced disease.